Business
Aussie biotech Starpharma signs deal to sell COVID nose spray in Britain – Sydney Morning Herald
The Melbourne-based firm’s market value is approaching the billion-dollar mark amid rising investor interest in its COVID-preventative treatment.
Australian biotech Starpharma is taking its COVID-fighting antiviral nasal spray to the world, signing a deal with UK chemist chain LloydsPharmacy to sell the product in Britain as the country emerges from lockdown.
The Melbourne-based company announced a deal on Thursday morning that will see its Viraleze virus-fighting product sold online in the UK starting next week. It will also be stocked in Lloyds 1400-strong pharmacy network.
Chief executive Jackie Fairley declined to comment on the value…
-
Business14 hours agoWarning! These ASX 200 shares were just downgraded
-
Business12 hours ago2 monthly payers you’ll want to own in 2025 and beyond
-
General23 hours agoTelco Exetel fined $694K after scammers bypass verification processes, access bank accounts
-
General22 hours agoSergio Perez and Valtteri Bottas to return to Formula 1 with Cadillac